Elevated CSF neurofilament levels are associated with risk of Mild Cognitive Impairment among individuals with and without low CSF amyloid-beta (P3.028)

摘要: Objective: To determine whether cerebrospinal fluid (CSF) neurofilament light (NfL) is associated with risk of mild cognitive impairment (MCI), and the association differs by CSF amyloid-beta (AB42) levels. Background: Previous studies have shown that elevated NfL levels, a measure axonal degeneration, decline hippocampal volume. Population-based are needed to factor for MCI, this AB42 Design/Methods: Analyses included 644 cognitively unimpaired Mayo Clinic Study Aging participants, aged 50–95. was measured using an in house sandwich enzyme-linked immunosorbent assay (ELISA) capture detection antibodies directed against central rod domain protein (NfL21 NfL23, respectively). AB42, total tau, ptau were automated electrochemiluminescence Elecsys immunoassays. The bottom tertile defined as having brain amyloid. Cox Proportional Hazards models, age timescale, used assess relationship between quartiles MCI after adjustment sex, education, APOE genotype Charlson comorbidity index. Models repeated stratifying low AB42. Results: participants followed median 3.66 years (range: 0.52–9.17). Compared quartile, top quartile more than 3-fold increased (HR: 3.56, 95% CI:1.54, 8.24) multivariate models. After stratification similarly among those 4.10, CI: 1.16, 14.53) without (HR:4.44, 1.34, 14.71) Conclusions: Elevated levels strongly community population. This independent Disclosure: Dr. Mielke has received personal compensation consulting, serving on scientific advisory board, speaking, or other activities Eli Lilly, Lysosomal Therapeutics, Inc. Syrjanen nothing disclose. Blennow Zetterberg Skoog Hagen Van Harten Knopman Lundbeck Pharmaceuticals DIAN study. Jack Petersen Roche, Inc., Merck, Biogen, Genentech, Kern